{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-25-001238","form_type":"8-K","ticker":"LCTC","cik":"0001493137","company_name":"Lifeloc Technologies, Inc","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.110698+00:00","generated_at":"2026-05-17T15:22:37.759670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lifeloc Q2 2025 net loss $(394k), revenue -7% YoY; SpinDx beta testing begins, launch expected early 2026","bullets":["Net revenue $2.219M, down 7% YoY; net loss $(394k) ($0.14 loss per share) vs $(298k) loss in Q2 2024.","Gross margin stable at 41.7%; R&D spend $623k primarily on SpinDx drug testing platform.","SpinDx beta testing underway for delta-9-THC detection; commercial launch targeted for early 2026.","Company began trading on OTCID tier of OTC Markets effective July 1, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-25-001238","json":"https://secwatch.observer/filing/0001079973-25-001238.json","markdown":"https://secwatch.observer/filing/0001079973-25-001238.md","text":"https://secwatch.observer/filing/0001079973-25-001238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1493137/000107997325001238/0001079973-25-001238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1493137/000107997325001238/lctc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:22:37.759670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}